Beyond the Classic: Atypical Dengue Presentations
Abstract
Dengue is an arthropod-borne viral infection caused by the dengue virus and spread by the vector Aedes mosquitoes. The clinical spectrum of dengue includes undifferentiated fever, dengue fever, dengue hemorrhagic fever, dengue shock syndrome, and expanded dengue syndrome (EDS). The patients may present with atypical symptoms and involve organs like the liver, kidney, brain, heart, bone marrow, and central nervous system. Three atypical dengue cases belonging to the EDS that had presented to the Emergency Department of a tertiary care center in Kerala, South India, are described in the case series. The first patient developed hemophagocytic lymphohistiocytosis secondary to dengue infection. The second patient had presented with altered mental status and was diagnosed with dengue encephalitis. The third patient had hyponatremia-syndrome of inappropriate anti-diuretic hormone secretion along with dengue infection. With a rapid increase in dengue cases worldwide, atypical presentations of dengue are no longer uncommon. Timely recognition and prompt management of the atypical presentation are needed, as many of the manifestations have serious outcomes. Hence, clinicians should be aware of the atypical manifestations of dengue.
How strong is the evidence?
Evidence Hub reads this as a case series, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.